1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
67BEB811DB01C160E652578490026879D
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/market-entry-pitfalls-to-avoid-product-risk-levels-market-physician-patient-payer-internal-and-regulatory?opendocument
18
19opendocument
2054.243.26.210
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Product Launch Influences on Market Entry

Pitfalls to Avoid for a Strong Market Entry: Current and Future Risk Levels for Product, Market, Physician, Patient, Payer, Internal and Regulatory Pitfalls

ID: 5121


Features:

15 Info Graphics

10 Data Graphics

100 Metrics

5 Narratives

3+ Best Practices


Pages/Slides: 33


Published: Pre-2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Pitfalls to Avoid for a Strong Market Entry: Current and Future Risk Levels for Product, Market, Physician, Patient, Payer, Internal and Regulatory Pitfalls"

STUDY OVERVIEW

For a new product to successfully enter the marketplace, organizations have to be vigilant of the many pitfalls that are part of the launch landscape. This research document highlights launch leaders' perspective on the current and future risk levels of potential pitfalls for critical launch factors such as product and market makeup, physicians, patients, payers, internal issues and regulatory. Pharmaceutical product launch leaders can use this study to better understand the potential pitfalls and stumbling blocks that they'll have to navigate as part of a new product entering the market.

KEY TOPICS

  • Pitfalls and Stumbling Blocks
  • Lessons learned, Best practices and Future changes

SAMPLE KEY METRICS

  • Estimate for the risk level of each product shaping pitfall that can derail a new product coming into a crowded market
  • Estimate for the risk level of each market shaping pitfall that can derail a new product coming into a crowded market
  • Estimate for the risk level of each physician pitfall that can derail a new product coming into a crowded market
  • Estimate for the risk level of each patient pitfall that can derail a new product coming into a crowded market
  • Estimate for the risk level of each payer stakeholder pitfall that can derail a new product coming into a crowded market
  • Estimate for the risk level of each internal failure point that can derail a new product coming into a crowded market
  • Estimate for the risk level of each regulatory pitfall that can derail a new product coming into a crowded market

SAMPLE KEY FINDING

  • Physician-Level Pitfalls: Key physician-related stumbling blocks reside with misalignment with thought leaders, missed KOLs/critical specialists, missed physician segments and limited health care access. Thought leaders & specialists are the highest risk physician stumbling blocks. Med education missteps can also be significant.
  • Payer Risk Factors: Payer risk factors are in high alert across multiple therapeutic areas and across many fronts: Misread pricing against generics, payer priorities and losing Managed Markets negotiations to competitors.

METHODOLOGY

The research employed a data gathering approach that gleaned quantitative data from 44 executives and managers from 38 leading companies in pharmaceutical, biotechnology and medical device industries. In addition, six executives participated in in-depth interviews.


Industries Profiled:
Pharmaceutical; Biotech; Medical Device; Health Care; Chemical; Manufacturing; Consumer Products; Diagnostic; Media


Companies Profiled:
Abbott Laboratories; Amgen; Actelion; AstraZeneca; GlaxoSmithKline; Bristol-Myers Squibb; Roche; Lilly; Novartis; Merck; Genentech; MedImmune; Bayer; Cephalon; Inc.; Teva Neuroscience; Novo Nordisk; Amylin; Laboratorios Deramtologicos Darier; IDS Canada; UCB Pharma; Quintiles; Ther-Rx; ProCaps Laboratories; Baxter Healthcare; Synapse biomedical; Talecris; Eisai; Shire; Takeda Pharmaceuticals


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.